WebAug 11, 2024 · Aug 11, 2024 Victoria Johnson PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain. Passage Bio has dosed the first patient with frontotemporal dementia with granulin mutations (FTD-GRN) with their gene therapy PBFT02 in the phase 1/2 upliFT-D study (NCT04747431). WebFeb 10, 2024 · PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, …
Passage Bio & Catalent Partner for Gene Therapy Manufacturing
WebAug 11, 2024 · PHILADELPHIA, Aug. 11, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous... WebJan 10, 2024 · PHILADELPHIA, January 10, 2024 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, will share the company's 2024 outlook in a presentation today at the 40 th Annual J.P. Morgan Healthcare Conference. hayle weather 21 days
Passage Bio : Announces 2024 Research and Clinical …
WebDec 14, 2024 · PHILADELPHIA, Dec. 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing … WebJan 24, 2024 · Passage Bio’s Programs One of the unique aspects of Passage Bio is its close relationship with the Gene Therapy Program (GTP) at the University of Pennsylvania, which is in James Wilson, M.D., Ph.D.’s laboratory. Chou says, “Jim Wilson and GTP at Penn execute on all our preclinical programs. WebMar 10, 2024 · PHILADELPHIA, March 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central... bottle and barlow barber